Check for updates

OPEN ACCESS

EDITED BY Han-Yu Deng, Sichuan University, China

REVIEWED BY Massimo Baudo, Lankenau Institute for Medical Research, United States Jia Huang, Shanghai Jiao Tong University, China

*CORRESPONDENCE Yunpeng Zhao Zhaoyunpengsddx@sdu.edu.cn Xiaogang Zhao Zhaoxiaogang@sdu.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 01 August 2024 ACCEPTED 22 October 2024 PUBLISHED 08 November 2024

CITATION

Ding Y, Zhou L, Shan L, Zhang W, Li P, Cong B, Tian Z, Zhao Y and Zhao X (2024) Video- assisted thoracoscopic lung resection with or without enhanced recovery after surgery: a single institution, prospective randomized controlled study. *Front. Oncol.* 14:1474438. doi: 10.3389/fonc.2024.1474438

COPYRIGHT

© 2024 Ding, Zhou, Shan, Zhang, Li, Cong, Tian, Zhao and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Video- assisted thoracoscopic lung resection with or without enhanced recovery after surgery: a single institution, prospective randomized controlled study

Yi Ding¹, Leiming Zhou², Lei Shan¹, Weiquan Zhang¹, Peichao Li¹, Bo Cong¹, Zhongxian Tian¹, Yunpeng Zhao^{1*†} and Xiaogang Zhao^{1*†}

¹Department of Thoracic Surgery, The Second Hospital of Shandong University, Jinan, China, ²Department of Thoracic Surgery, People's Hospital of Laoling, Laoling of Dezhou, China

Purpose: This study was conducted to evaluate the postoperative short-term outcomes of patients undergoing video-assisted thoracoscopic surgery (VATS) for lung resection with the enhanced recovery after surgery (ERAS) protocol.

Methods: A single-institution, prospective randomized controlled study was conducted. The primary outcome measures were postoperative pulmonary complications (PPCs) and postoperative short-term effects.

Results: Among the 611 patients, 305 were assigned to the ERAS group, and 306 were assigned to the routine group. The ERAS group achieved earlier oral feeding, earlier mobilization, a shorter duration of drainage (2.0 vs. 5.0 days, P<0.001), and a shorter hospital stay (3.0 vs. 7.0 days, P<0.001). The biological impacts were confirmed to be significantly better for the ERAS group. Furthermore, the ERAS group also had a lower incidence of PPCs (11.5% vs. 22.9%, P<0.001) than did the routine group. Multivariate logistic regression analysis revealed the following predictors of drainage tube removal on the 1st day after surgery without pneumonia during hospitalization: comorbidity (P=0.029), surgical procedure (P=0.001), and operation time (P=0.039).

Conclusions: Implementation of the ERAS protocol led to a decreased incidence of PPCs, suggesting that the ERAS protocol has a better biological impact on patients undergoing VATS for lung resection. Multigradient individual ERAS protocols are recommended at different institutions according to the individual conditions of patients.

Clinical Trial Registration: https://register.clinicaltrials.gov/prs/app/action/ SelectProtocol?sid=S0009ZT9&selectaction=Edit&uid=U0002ZGN&ts=3&cx= ks7hrg, identifier NCT04451473.

KEYWORDS

enhanced recovery after surgery, lung resection, thoracic surgery, postoperative pulmonary complications, day surgery

Introduction

Enhanced recovery after surgery (ERAS) was first reported in the late 1990s (1). ERAS strategies involve all aspects of perioperative care, aiming to improve patient prognosis, reduce complications, shorten hospital stays, and lower costs (2–6). The concept of ERAS has been applied in open or minimally invasive surgeries, including colorectal surgery (7), gynecological surgery (8), liver surgery (9), breast surgery (10), urological surgery (11), and spinal surgery (12).

Thoracic surgery is considered an invasive and traumatic procedure for patients (13). Minimally invasive surgeries, including video-assisted thoracoscopic surgery (VATS), have been widely used for surgical treatment (14, 15). Thoracic surgery has undergone two major advancements: one is the switch from open surgery to minimally invasive surgery, and the other is the use of structured clinical pathways based on ERAS guidelines (16, 17). Studies have also focused on ERAS strategies for thoracic surgery in recent years (18), especially in VATS for lung resection (19, 20), indicating that ERAS can efficiently minimize surgical trauma, improve the quality of postoperative recovery, and decrease financial burdens. However, the outcome data of ERAS programs applied for lung resection are limited, and more diverse regions of study are needed to determine the safety and effectiveness of ERAS strategies. The aim of this study was to determine the impact of the ERAS pathway on the short-term outcomes of patients who underwent lung resection.

Patients and methods

Patient eligibility

The inclusion criteria for patients were as follows (1): had lung lesions suitable for VATS, including benign and malignant lesions diagnosed by CT (enhanced or nonenhanced) or pathological results (2); were aged between 18 and 85 years (3); had a Karnofsky score \geq 80 along with cardiopulmonary function, liver function, and renal function indicating the ability to tolerate minimally invasive surgery (4); had normal cognitive function and was able to cooperate with the rehabilitation training (21, 22); and (5) agreed on the protocol of the clinical trial and signed the consent form.

The exclusion criteria for patients were as follows (1): refused randomization (2); was unable to cooperate with the rehabilitation training or tolerate minimally invasive surgery due to cognitive or physical dysfunctions; and (3) participated in other clinical trials or had received treatment with anticancer drugs in other clinical trials.

Pretreatment workup

The study was approved by the Ethics Committee of the Second Hospital of Shandong University (SDDXDEYY-KYB-2020053). The study's registration information is as follows: Clinical Trials. Gov ID: NCT04451473 (30/06/2020). Informed consent was obtained from all the patients. Our work was fully compliant with the CONSORT criteria, and this study is reported in line with the CONSORT criteria (23). We confirmed that all methods were performed in accordance with the relevant guidelines and regulations.

Randomization and allocation

This study was designed as a single-center, randomized, unblinded control trial. Random assignment was performed using the envelope method by a statistician at the Evidence-based Medicine Center of the Second Hospital of Shandong University. Once an informed consent form was signed, the patient was assigned to one group by opening the sequentially numbered envelope (24).

Study interventions

Control group (routine group)

The patients were randomly assigned to the control group (routine group) and received standard VATS; however, the perioperative management was mainly traditional without systemic ERAS protocol guidance. The traditional management methods were as follows: 1. the patient received no systemic physical pulmonary training before surgery; 2. the patient received sedatives to reduce anxiety preoperatively; 3. the patient fasted from solids for at least 8 hours and from liquids for at least 6 hours; 4. a transurethral catheter was routinely placed and then removed on the second day after surgery; 5. the patient remained completely supine for 6 hours after surgery; 6. the patient fasted from solids and liquids for 6 hours after surgery; 7. the patient achieved ambulation \geq 24 hours after surgery; 8. two chest tubes were used when the upper lobe was moved; 9. the chest tube was removed when the highest volume did not exceed 100 ml/24 h; and 10. opioids were the most common drugs in the analgesic regime.

Intervention group (ERAS group)

The ERAS protocol was performed mainly according to two guidelines (16, 17), and physical pulmonary training in the general ward was recommended according to the protocol (25). The core items of ERAS application at our institution are shown as following:

1. Dedicated preoperative counseling and education should be given in the preoperative phase. Nutritional status screening and improvement, smoking cessation (2-4 weeks), alcohol dependency management, and even pulmonary prehabilitation (according to the patient's cognitive ability and compliance) should also be accomplished in this phase.

2. Airway management during the preoperative examination after admission: climbing stairs or power-based cycling, which can enhance cardiopulmonary function, has often been used in the past few years; however, physical pulmonary training in the general ward is strongly recommended (25), especially during the COVID-19 pandemic, which has been ongoing since 2020. Education and training are better guided by a physiotherapist or by a charge nurse.

3. Aspirin withdrawal is not recommended for patients in the ERAS group unless VATS is complicated and accompanied by a high risk of bleeding. Low molecular weight heparin bridging treatment is used during aspirin withdrawal.

4. Sedatives for reducing anxiety preoperatively are prohibited.

5. Clear fluids are allowed up until 2-4 h before the induction of anesthesia, and oral carbohydrate loading can be used routinely.

6. A combination of regional and general anesthetic techniques should be used, and general anesthesia combined with nonintubated spontaneous breathing can be an alternative to double-lumen intubation if the anesthesiologist has mastered the technique.

7. Uniport VATS was routine for patients in the ERAS group. Wedge resection or segmentectomy should be meticulously planned through the scientific reading of thin-slice CT or 3D simulation before surgery. High-quality minimally invasive surgery is the foundation of ERAS protocol implementation.

8. A transurethral catheter is not routinely placed for the sole purpose of monitoring urine output without thoracic epidural anesthesia. Transurethral catheters can be used in one of the following conditions (1): the estimated operation time is more than 150 minutes or even 180 minutes (2); high risk of bleeding; and (3) critical patients with organ dysfunction. If the operation takes a longer time than expected without a urinary catheter, placing a disposable catheter is reasonable. The urinary catheter should be removed immediately after the operation if the patients' respiratory and circulatory status is stable without prediction advanced life support. 9. The head of bed (by \geq 30°) was immediately raised when the patient went back to the general ward. The patient could sit up straight with the help of the charge doctor or charge nurse 2 hours after returning to the ward, and the patient was asked to drink a little water if no postoperative nausea and vomiting (PONV) occurred; otherwise, PONV was treated using nonpharmacological control with or without pharmacological control [16] according to the degrees of discomfort. A small portion of a semifluid diet was encouraged if no PONV occurred. Then, the nutrition procedures could be conducted by specialized nutritionists from the Nutrition Department.

10. Early ambulation evaluation began when the patients could sit up straight 2 hours after returning to the ward. If the patient can keep the straight sitting position without obvious dizziness and weakness, he or she can try to leave the bed and stand beside the sickbed with electrocardiogram monitoring. Marching on the spot can be started if the vital signs and respiratory status remain stable, and then moderate ambulation can be tried with the accompaniment of medical staff and a family member.

11. A single tube was used for the patients in the ERAS group, and the chest tube was removed when the following conditions were met (1): no progressive bleeding or chylothorax (2); no persistent air leakage during continuous cough (3); no obvious atelectasis confirmed by physical examination or imaging examination; and (4) daily serous effusion less than 300 ml/24 h, with the highest volume not exceeding 450 ml/24 h.

12. A multimodal analgesic regimen is recommended for pain relief (16, 17). Opioids are inevitable in most cases, but they should be minimized. Patient education is important but not enough for anxious patients or patients suffering from severe pain, needing psychological counseling and needing additional techniques such as transcutaneous electrical nerve stimulation (TENS).

Withdrawal from the trial

Patients were withdrawn for one of the following reasons: (i) a withdrawal request was made by the patient or the family member; (ii) there was poor compliance with the training protocol; or (iii) severe complications, such as heart disease or stroke, occurred.

Sample size calculation

Several primary or secondary outcomes have been studied; however, postoperative pulmonary complications (PPCs) are an important and widely used index for evaluating short-term postoperative improvement (26). The criteria for PPCs were established according to the STS/ESTS definitions (27). It has been reported that the ERAS group has a lower incidence of PPC than the routine group (15.2% vs. 19.5%, P=0.022) (28). For this trial, a minimum 10% absolute risk reduction from a 19.5% PPC risk was set (25). A significant difference between groups was detected with a sample of 480 patients (p = 0.05, 80% power of test, two-sided test), considering a 20% inflation in the case of dropouts and a final sample size of 600.

TABLE 1 Patients' characteristics of the study population.

Age, yearsinterquantile angueinterquantile angue <th>Characteristics</th> <th>ERAS group (=305)</th> <th>Routine group (n=306)</th> <th>P value</th>	Characteristics	ERAS group (=305)	Routine group (n=306)	P value
Median58591Interquatile range51-6653-661Range18-8328-831Gender, n(%)140 (45.7%)160 (52.3%)1Female165 (54.1%)160 (52.3%)64 (21.0%)Forking status, n(%)250 (82.0%)64 (21.0%)0.913Never250 (82.0%)64 (21.0%)0.913Pyerension7964 (21.0%)0.913Jhyerension79791Jiabets mellitus303.631Jiabets mellitus303.641GODP ³ 10109.0211Malignant tumor202211Adenocarcinoma20021011Malignant tumor585111Adenocarcinoma585111Sclerosing pneumocytoma2211Sclerosing pneumocytoma2211Tis79111Tis79111Tis79111Tinin314.3111Tis79111Tis79111Tis79111Sclerosing pneumocytoma1511.3311Tis79111Tis791 <td>Age, years</td> <td></td> <td></td> <td>0.671</td>	Age, years			0.671
Interquatile range51-6653-66.Range18-8328-83.Gender, n (%)140 (45.9%)146 (47.7%).Female165 (54.1%)160 (52.3%).Forking status, n (%)250 (82.0%)64 (21.0%).Ever55 (18.0%)64 (21.0%).Never250 (82.0%)242 (79.0%).Inver250 (82.0%)242 (79.0%).Diabets mellitus3036.Diabets mellitus3036.Diabets mellitus2022.2.Dropp'109Malignant tumor2022.0.Malignant tumor264269.Malignant tumor5851.Granuloma or infinmantionSclerosing pneumocytoma20Sclerosing pneumocytoma2Tis79Tis79Tinin3143Tinin31Tis79Tis79TisTisNoSclerosing pneumocytomaTisTis	Median	58	59	
Range18-8328-830.0554Gender, n(%)140 (45.9%)146 (47.7%)0.051Male165 (54.1%)160 (52.3%)0.012Fomale55 (18.0%)64 (21.0%)0.012Ever55 (18.0%)64 (21.0%)0.013Never250 (82.0%)242 (79.0%)0.013Deter250 (82.0%)242 (79.0%)0.013Merer250 (82.0%)0.242 (79.0%)0.013Diabets mellitus3064 (21.0%)0.013Diabets mellitus30360.013Diabets mellitus30360.013Diabets mellitus30360.013GODP3109.020.016Malignant tumor2642000.016Squamous cell carcinoma58510.016Granuloma or infinamation20260.016Granuloma or infinamation202.020.016Selerosing pneumocytoma202.020.016Selerosing mperumocytoma2.022.020.026Tis790.0260.026Tini314.340.0210.026Tis790.0210.021Tis7115214.30.021Tis73201.740.021Tis201.740.020.026Tis732.021.740.021Tis743.01.040.021Tis7.1	Interquartile range	51-66	53-66	
Gender, n (%)IdeIde (47.7%)0.654Male140 (45.7%)146 (47.7%)IFenale165 (54.1%)160 (52.3%)0.412Smoking status, n (%)55 (18.0%)64 (21.0%)IEver55 (18.0%)64 (21.0%)0.113Never250 (82.0%)242 (79.0%)0.113Image status250 (82.0%)242 (79.0%)0.113Merer250 (82.0%)79.0%0.113Image status7979.0%0.113Image status3036.0%1.116Image status2022.0%0.116Image status2021.0%0.680Malignant tumor2042.10%0.680Squamous cell carcinoma3332.0%1.116Granuloma or infinamation202.10%1.116Granuloma or infinamation2.0%3.12%1.116Splerosing promocytoma2.0%2.12%1.116Tis7.13.13.14%1.116Tis7.13.13.14%1.116Ti3.1%3.14%3.14%1.116Ti3.1%3.14%3.14%1.116Ti3.1%3.14%3.14%1.116Ti3.1%3.14%3.14%1.116%Ti3.1%3.14%3.14%1.116%Ti3.1%3.14%3.14%1.116%Ti3.1%3.14%3.14%1.116%Ti3.1%3.14%3.14%	Range	18-83	28-83	
Male140 (45.9%)146 (47.7%)7Fenale165 (34.1%)160 (52.3%)0.412Smoking status, n(%)55 (18.0%)64 (21.0%)7Iver250 (82.0%)242 (79.0%)0.913Never250 (82.0%)242 (79.0%)0.913Jonders250 (82.0%)242 (79.0%)0.913Image: Status norm250 (82.0%)3.040.913Jubetes mellitus3.03.641.01Jubates mellitus3.03.641.01Jeant vascular disease2.02.20.01CODP ¹ 1090.680Malignant tumor2.642.690.680Squamous cell2.02.101.01Squamous cell3.32.101.01Stage for Malignant2.03.321.01Sclerosing pneumocytoma2.02.21.01State for Malignant3.14.31.01Tis791.011.01Tis791.011.01Tis7.13.13.141.01Tinin3.13.141.011.01Ti A3.01.113.141.01Ti A3.13.141.011.01Ti A3.13.141.011.01Ti A3.13.141.011.01Ti A3.13.141.011.01Ti A3.13.143.141.01Ti A3.13.143	Gender, n (%)			0.654
Fenale155 (14.0%)160 (52.3%)0.412Smoking status, n (%)55 (18.0%)64 (21.0%)1Iver250 (82.0%)242 (79.0%)0.913Never250 (82.0%)799Comorbidity79799Jhypertension79791Diabetes mellitus30361Brain vascular disease2022.01COPD*1090.680Malignant tumor2642691Squamous cell carcinoma58511Other6481Benign tumor20261Squamous cell carcinoma33321Stage for Malignant pneumocytoma2021Tis7991Tis7911Tinfalmation11521431Tis791Tis791Tis791Tis31431Ti A3011Ti A341Ti A2	Male	140 (45.9%)	146 (47.7%)	
Smoking status, n(%)00.412Ever55 (18.0%)64 (21.0%)1Never250 (82.0%)242 (79.0%)0.913Comorbidity79799Jubetes79791Diabetes mellitus30361Hart disease2022.01COPD*1091Pathological type202106.680Malignant tumor2642691Squamous cell58511Granuloma or inflammation33321Selerosing pneumocytoma20261States for Malignant1141Tis791Tis791Tis791Tis31431Tis711531Tis20171States for Malignant1431Tis791Tis51531Tis20171Tis31431Tis51531Tis20171Tis666States for Malignant2017Tis20171Tis20171Tis20171Tis20171Tis20171Tis20 <td>Female</td> <td>165 (54.1%)</td> <td>160 (52.3%)</td> <td></td>	Female	165 (54.1%)	160 (52.3%)	
Ever55 (18.0%)64 (21.0%)1Never250 (82.0%)242 (79.0%)0.913Comorbidity7999Hypertension7999Diabetes mellitus30361Brain vascular disease24201COPD*1091Pathologicat type220.680Malignant tumor2642691Squamous cell carcinoma58511Other681Granuloma or inflammation202101Granuloma or inflammation202101Sclerosing pneumocytoma20261Tis7911Tis791111431431Tini314311Tis7911Tis7911Timi314311Tis201711Tis7911Tis7911Timi314311Tis7911Tis515311Tis201711Tis201711Tis515311Tis201711Tis20 </td <td>Smoking status, n (%)</td> <td></td> <td></td> <td>0.412</td>	Smoking status, n (%)			0.412
Never250 (82.0%)242 (79.0%).Comorbidity	Ever	55 (18.0%)	64 (21.0%)	
Comorbidity00.913Hypertension7979Diabetes mellitus3036Heart disease2420Brain vascular disease2022COPD*109Pathological type0.680Malignant tumor264269Adenocarcinoma200210Squamous cell carcinoma5851Other682Granuloma or inflammation3332Granuloma or inflammation2026Sclerosing pneumocytoma22Stage for Malignant tumor85Tis79Tis79Tis79Tia152143Tia3143Tia2017Stage for Malignant tumor3143Ti320.698No225300.698Ni225301	Never	250 (82.0%)	242 (79.0%)	
Hypertension797979Diabetes mellitus30361Heart disease24201Brain vascular disease20221COPD*1090Pathological type0.6800.680Malignant tumor2642691Squamous cell carcinoma58511Other681Other681Granuloma or inflammation20261Sclerosing pneumocytoma20261Stage for Malignant tumor1141Tis791Tis791Tis711431Ti1521431Ti20171Stage for Malignant tumor31431Ti Ata31431Ti Ata31431Ti Ata31431Ti Ata31431Ti Ata3411Ti Ata341Ti Ata340.698No225301Ni25301	Comorbidity			0.913
Diabetes mellitus3036IHeart disease242021Brain vascular disease2022ICOPD*109IPathological type0.6800.680Malignant tumor264269IAdenocarcinoma200210ISquamous cell carcinoma5851IOther68IBenign tumor3332IGranuloma or inflammation2026ISclerosing pneumcytoma22ISclerosing pneumcytoma22ITis79ITis79ITini3143IT1152143IT32017IT434IN022530IN12530IN21417I	Hypertension	79	79	
Heart disease242010Brain vascular disease2022COPD ^a 109Pathological type0.680Malignant tumor264269Adenocarcinoma200210Squamous cell carcinoma5851Other68Benign tumor3332Hamartoma114Granuloma or inflammation2026Sclerosing pneumocytoma22Sclerosing pneumocytoma22Tis79Timi3143T1152143T15153Tis79Tini3143T15153Ti3143Ti3143Ti3143Ti3143Ti3143Ti5530N022530N12530	Diabetes mellitus	30	36	
Brain vascular disease2022COPDa109Pathological type0.680Malignant tumor264269Adenocarcinoma200210Squamous cell carcinoma5851Other681Other681Granuloma or inflammation2026Sclerosing pneumocytoma22Sclerosing pneumocytoma22Tis79Timi3143Tini3143Tini3143Tia2017Timi3143Timi3143Timi3143Timi3143Timi3143Timi3144Timi3144Timi3144Timi3144Timi3144Timi3144Timi3144Timi3144Timi3144Timi3144Timi3144Timi3232Timi3232Timi3234Timi3232Timi3233Timi3234Timi3535Timi3536Timi3134Timi3134Timi3133 <td>Heart disease</td> <td>24</td> <td>20</td> <td></td>	Heart disease	24	20	
COPDa109Pathological type0.680Malignant tumor264269Adenocarcinoma200210Squamous cell carcinoma5851Other6810Other6810Benign tumor333210Granuloma or inflammation2026100Sclerosing pneumocytoma220Pulmonary bulla850.723Tis790.723Tis790.723Tini31430.723Ti15211430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti31430.723Ti321170.698No2252220.698Ni23300.698Ni321417	Brain vascular disease	20	22	
Pathological type0.680Malignant tumor264269Adenocarcinoma200210Squamous cell carcinoma5851Other68Benign tumor3332Hamartoma114Granuloma or inflammation2026Sclerosing pneumocytoma22Pulmonary bulla85Tstage for Malignant tumor79Tis79Tini3143T1152143T25153T32017T434N0225222N12530N21417	COPD ^a	10	9	
Malignant tumor264269Adenocarcinoma200210Squamous cell carcinoma5851Other68Benign tumor3332Hamartoma114Granuloma or inflammation2026Sclerosing pneumocytoma22Pulmonary bulla85Tis79Timi3143T1152143T15153T25153T32017T434N0225222N12530N21417	Pathological type			0.680
Adenocarcinoma200210Squamous cell carcinoma5851.Other68.Benign tumor3332.Hamartoma114.Granuloma or inflammation2026.Sclerosing pneumocytoma22.Pulmonary bulla85.Tstage for Malignant tumor3143.T1152143.T1152143.T25153.T32017.T434.N0225222.N12530.N21417.	Malignant tumor	264	269	
Squamous cell carcinoma5851IOther681Benign tumor33321Hamartoma1141Granuloma or inflammation20261Sclerosing pneumocytoma222Pulmonary bulla851T stage for Malignant tumor790.723Tis7911T11521431T251531T320171T4341N02252222N125301N214171	Adenocarcinoma	200	210	
Other68Benign tumor3332Hamartoma114Granuloma or inflammation2026Sclerosing pneumocytoma22Pulmonary bulla85T stage for Malignant tumor79Tis79T1mi3143T25153T32017T434No225222N12530N21417	Squamous cell carcinoma	58	51	
Benign tumor3332Hamartoma114Granuloma or inflammation2026Sclerosing pneumocytoma22Pulmonary bulla85T stage for Malignant tumor0.723Tis79T1mi3143T1152143T25153T32017T434No225222N12530N21417	Other	6	8	
Hamartoma114Granuloma or inflammation2026Sclerosing pneumocytoma22Pulmonary bulla85T stage for Malignant tumor0.723Tis79T1mi3143T1152143T25153T32017T434No225222N12530N21417	Benign tumor	33	32	
Granuloma or inflammation2026Sclerosing pneumocytoma22Pulmonary bulla85T stage for Malignant tumor0.723Tis79Timi3143T1152143T25153T32017T434No225222N12530N21417	Hamartoma	11	4	
Sclerosing pneumocytoma22Pulmonary bulla85T stage for Malignant tumor0.723Tis79T1mi3143T1152143T25153T32017T434No225222N12530N21417	Granuloma or inflammation	20	26	
Pulmonary bulla85T stage for Malignant tumor0.723Tis79Tis79T1mi3143T1152143T25153T32017T434No225222N12530N21417	Sclerosing pneumocytoma	2	2	
T stage for Malignant tumor0.723Tis79Tlmi3143T1152143T25153T32017T434No225222N12530N21417	Pulmonary bulla	8	5	
Tis 7 9 T1mi 31 43 T1 152 143 T2 51 53 T3 20 17 T4 3 4 Nstage for Malignant tumor 0.698 N0 225 222 N1 25 30 N2 14 17	T stage for Malignant tumor			0.723
T1mi 31 43 T1 152 143 T2 51 53 T3 20 17 T4 3 4 N stage for Malignant tumor 225 222 N1 25 30 N2 14 17	Tis	7	9	
T1 152 143 T2 51 53 T3 20 17 T4 3 4 N stage for Malignant tumor 225 222 N1 25 30 N2 14 17	T1mi	31	43	
T2 51 53 T3 20 17 T4 3 4 N stage for Malignant tumor 0.698 N0 225 222 N1 25 30 N2 14 17	T1	152	143	
T3 20 17 T4 3 4 N stage for Malignant tumor 0.698 N0 225 222 N1 25 30 N2 14 17	T2	51	53	
T4 3 4 N stage for Malignant tumor 0.698 N0 225 222 N1 25 30 N2 14 17	Т3	20	17	
N stage for Malignant tumor 0.698 N0 225 222 N1 25 30 N2 14 17	T4	3	4	
N0 225 222 N1 25 30 N2 14 17	N stage for Malignant tumor			0.698
N1 25 30 N2 14 17	N0	225	222	
N2 14 17	N1	25	30	
	N2	14	17	

TABLE 1 Continued

Characteristics	ERAS group (=305)	Routine group (n=306)	P value
LNs ^b station dissected			0.201
Median	4	5	
Interquartile range	4-5	4-6	
Range	1-10	2-8	
LNs ^b amount dissected			0.183
Median	8	9	
Interquartile range	6-13	7-13	
Range	2-32	3-36	
Pulmonary function			
FEV1 ^c (L)			0.210
Median	2.28	2.24	
Interquartile range	1.94-2.73	1.88-2.70	
Range	1.11-4.85	1.05-4.78	
MVV ^d (L)			0.485
Median	91.2	89.6	
Interquartile range	79.4-103.2	78.9-103.8	
Range	63.8-118.5	64.6-115.9	
Surgical procedures			0.061
Lobectomy	163	184	
Segmentectomy	55	35	
Wedge resection	87	87	
Operation time (minutes) mean <u>+</u> SD			0.150
Median	60	60	
Interquartile range	45-90	45-88	
Range	20-240	25-240	
Intraoperative blood loss (mL), mean \pm SD			0.946
Median	50	50	
Interquartile range	40-60	40-60	
Range	20-500	20-400	
VATS surgery converted			0.452
to open (%)	9 (3.0%)	6 (2.0%)	

^aCOPD, chronic obstructive pulmonary disease.

^bLNs, lymph nodes.

^cFEV1, forced expiratory volume in 1.0 s. ^dMVV, maximum volume for ventilation.

Outcome measures and statistical analysis

The primary outcome measures were PPCs. The secondary outcome measures were some other postoperative short-term effects, postoperative long-term respiratory function, healthrelated quality of life (HRQoL), progression-free survival (PFS) and overall survival (OS) for patients who underwent VATS for

TABLE 2 Postoperative recovery of our study population.

Characteristics	ERAS group (n=305)	Routine group (n=306)	P value
Water feeding 2 hours after RTW ^a (%)	210 (68.9%)	0 (%)	<0.001
Semi- fluid diet within 3 hours after RTW ^a (%)	103 (33.8%)	0 (%)	<0.001
Postoperative moderate ambulation on the surgery day (%)	114 (37.4%)	7 (2.3%)	<0.001
Duration of drainage (day)			<0.001
Median	2	5	
Interquartile range	1-2	4-6	
Range	1-8	2-11	
Postoperative hospital stay (day)			< 0.001
Median	3	7	
Interquartile range	2-4	6-8	
Range	1-13	2-15	
Request extension of hospital stay without objective complications (%)	61 (20.0%)	32 (10.5%)	0.001
Readmission rate within 14 days after surgery (%)	6 (2.0%)	3 (1.0%)	0.340

^aRTW, Return to ward.

lung cancer surgery. Continuous variables are expressed herein as means and standard deviations (SDs); data that were not normally distributed are presented as medians and ranges; and binary variables are presented as proportions. The data were evaluated through Student's t test (data matching a normal distribution), nonparametric statistics, the chi-square test, or Fisher's exact test, as appropriate. Multivariate logistic regression analysis was used to reveal the predictors of drainage removal on the first day after surgery without pneumonia during hospitalization. Statistical analysis and graph generation were performed with Stata 12.0 (StataCorp LP, College Station, TX, USA) at a significance level of 0.05. Multivariate logistic regression analysis was performed with SPSS statistics software (version 25; SPSS, Inc., Chicago, IL).

Results

Patient characteristics

From July 2020 to June 2022, 611 patients were enrolled in the study; 305 patients were assigned to the ERAS group, and 306 were assigned to the routine group. The treatment protocol was completed for the enrolled patients. The patient characteristics were balanced between the two groups (Table 1).

As shown in Table 2, 210 patients (68.9%) were able to drink water 2 hours after returning to the general ward in the ERAS group, 103 patients (33.8%) had a semifluid diet within 3 hours after returning to the general ward in the ERAS group, and 114 patients (37.4%) had moderate postoperative ambulation on the surgery day with guidance and an accompanying medical staff member and family member. The following three characteristics were significantly different between the ERAS group and the routine group: The duration of drainage in the ERAS group was significantly shorter than that in the routine

group (median, 2 days with IQR 1-2 days vs. median, 5 days with IQR 4-6 days). The median postoperative hospital stay was 3 days (IQR, 2-4 days) in the ERAS group, and the median postoperative hospital stay was significantly longer (7 days, IQR, 6-8 days; P <0.001) in the routine group. The readmission rate within 14 days after surgery was similar: 2.0% (6 patients) in the ERAS group and 1.0% (3 patients) in the routine group (P=0.340). No mortality within 30 days occurred in both groups.

Postoperative blood samples were collected and tested two days after surgery (Table 3) unless the patients were discharged from the hospital the first day after surgery (10 patients in the ERAS group). The postoperative white blood cell (WBC) count, percentage of neutrophil granulocytes (NEUT%), and postoperative C-reactive protein (CRP) level were significantly different between the ERAS group and the routine group (p = 0.032; p < 0.001; p = 0.023, respectively). Postoperative procalcitonin (PCT) was not significantly different between the two groups (P=0.566). The median albumin (ALB) level was 38.1 in the ERAS group (IQR, 35.4-40.7 g/L) and 37.6 in the routine group (IQR, 34.7-39.5 g/L; P=0.010). The median prealbumin (PA) level was 20.5 in the ERAS group (IQR, 17.6-23.2 mg/dL) and 15.5 in the routine group (IQR, 13.0-18.7 mg/dL; P<0.001).

The postoperative early complications are shown in Table 4. For pulmonary complications (PPCs), 11.5% of the patients in the ERAS group had pulmonary complications, 22.9% of the patients in the routine group had pulmonary complications, and the difference was significant (P<0.001). There were greater incidences of atelectasis and air leakage in the routine group (P=0.046; P=0.003). Bronchopleural fistula and respiratory failure rarely occurred in either group. The occurrence of supraventricular arrhythmia, acute myocardial infarction, acute cerebral stroke, and venous thromboembolism was similar in both groups. Significantly more urinary irritation was observed in the routine group (ERAS

TABLE 3 Blood laboratory examination of our study population.

Characteristics	ERAS group(n=305)	Routine group (n=306)	P value
Postoperative white blood cell (10^9)			0.032
Median	11.75	12.26	
Interquartile range	10.2-13.83	10.55-14.91	
Range	7.1-25.82	7.01-25.17	
Postoperative NEUT% ^a			< 0.001
Median	82.1	84.4	
Interquartile range	79.8-85.5	81.3-86.9	
Range	58.5-94.9	63.3-94.6	
Postoperative CRP ^b (mg/L)			0.023
Median	109.0	117.1	
Interquartile range	66.2-149.9	86.2-150.0	
Range	18.1-267.7	19.2-263.1	
Postoperative PCT ^c (ng/ml)			0.566
Median	0.234	0.186	
Interquartile range	0.10-1.427	0.105-0.37	
Range	0.02-10.16	0.02-6.86	
Postoperative ALB ^d (g/L)			0.012
Median	38.1	37.6	
Interquartile range	35.4-40.68	34.7-39.5	
Range	21.4-51.4	23.9-52.5	
Postoperative PA ^e (mg/dL)			<0.001
Median	20.5	15.5	
Interquartile range	17.6-23.2	13.0-18.7	
Range	5.7-30.4	4.0-27.9	

^aNEUT%, percentage of neutrophile granulocytes.

^bCRP, C-reactive protein.

^cprocalcitonin.

dalbumin

^eprealbumin

group: 6.2%, routine group: 25.5%; P<0.001), and the frequency of acute urinary retention was similar between the two groups (ERAS group: 0.7%, routine group: 1.6%; P=0.449).

Multivariate logistic regression analysis was used to reveal the predictors of PPCs. Table 5 shows that age (P=0.014), ERAS management (P=0.004) were significant predictors. Gender and surgical procedures seemed to have the trend, but neither of them showed the significant statistical difference (P=0.062, P=0.066 respectively).

Multivariate logistic regression analysis was also used to reveal the predictors of drainage tube removal on the 1st day after surgery without causing pneumonia during hospitalization. Table 6 shows that comorbidity (P=0.029), surgical procedure (P=0.001) and operation time (P=0.039) were significant predictors. Rapid removal of chest drainage tubes and recovery without pneumonia

TABLE 4 Postoperative early complications of our study population.

Characteristics	ERAS group (n=305)	Routine group (n=306)	P value
PPCs ^a (%)	35 (11.5%)	70 (22.9%)	< 0.001
Pneumonia	17 (5.6%)	27 (8.8%)	0.163
Atelectasis	13 (4.3%)	25 (8.2%)	0.046
Air leak (≥5 days)	6 (2.0%)	22 (7.2%)	0.003
Bronchopleural fistula	1 (0.3%)	1 (0.3%)	1.000
Respiratory failure	2 (0.7%)	3 (1.0%)	1.000
Supraventricular arrhythmia (%)	7 (2.3%)	12 (3.9%)	0.348
Acute myocardial infarction (%)	0 (0%)	1 (0.3%)	1.000
Acute cerebral stroke (%)	1 (0.3%)	2 (0.7%)	1.000
VTE ^b (%)	0 (0%)	2 (0.7%)	0.497
Urinary irritation (%)	19 (6.2%)	78 (25.5%)	< 0.001
Acute urinary retention (%)	2 (0.7%)	5 (1.6%)	0.449

^aPPCs, pulmonary complications. Four patients in ERAS group had \ge 2 PPCs, eight patient in Routine group had \ge 2 PPCs.

^bvenous thromboembolism, including deep venous thrombosis (DVT) and pulmonary thromboembolism (PTE).

may constitute the foundation of day surgery (from admission to discharge \leq 48 hours).

Discussion

In recent years, increasing attention has been given to the implementation of ERAS protocols for various tumors (29–31). The ERAS program for lung surgery (16, 17) was described relatively late and was aimed to decrease postoperative morbidity and mortality.

In the traditional postoperative management mode, patients were asked to stay in the supine posture without drinking or eating for at least 6 hours. Patients were not required to remain in the supine position or fast for a long period when the combination of regional and general anesthetic techniques was used. Patients in the ERAS group were allowed to drink water and have a semifluid diet so that specialized nutritionists could use an earlier intervention. Even more than one-third of the patients in the ERAS group achieved moderate ambulation on the day of surgery, and this approach has been confirmed to be feasible and safe (32). Although contrary to the ERAS protocol, the chest drainage tube could be removed when the volume was less than 100 ml in the traditional mode. However, we suggest careful consideration of early removal of the drainage system, as this approach is relied on successful highquality minimally invasive surgery, early oral feeding and ambulation. In this study, the ERAS group had a median postoperative hospital stay of 3 days (interquartile range: 2-4 days), which was still shortened gradually.

TABLE 5 Predictors of PPCs.

Predictor ^a	β value	Odds ratio (95% CI)	P value
Gender	0.634	1.884 (1.024- 3.468)	0.062
Age	0.039	1.040 (1.008- 1.073)	0.014
Smoking status	0.124	1.132 (0.641- 2.000)	0.669
Comorbidity	0.216	1.241 (0.893- 1.724)	0.197
Convert to open	0.052	1.062 (0.317- 3.132)	0.932
Surgical procedures	0.358	1.430 (0.977- 2.096)	0.066
Operation time	0.004	1.004 (0.995- 1.012)	0.397
Intraoperative blood loss	0.001	1.001 (0.996- 1.006)	0.800
ERAS management	-0.880	0.415 (0.229- 0.751)	0.004

^aMultivariate logistic regression analysis: gender (female: 0, male: 1), age (numerical variable), smoking status (never: 0, ever: 1), comorbidity (hypertension, diabetes mellitus, heart disease, brain vascular disease, COPD, no comorbidity: 0, one comorbidity: 1, two comorbidities: 2, \geq 3 comorbidities: 3), Convert to open (no: 0, yes: 1), surgical procedures (wedge resection: 0, segmentectomy: 1, lobectomy: 2), operation time (minutes, numerical variable), intraoperative blood loss (ml, numerical variable), ERAS management (no: 0, yes: 1), PPCs (no PPCs: 0, PPCs: 1).

The biological impact, which was also investigated in our study, has been investigated in several other organ surgeries within the ERAS program (33-35). Blood laboratory examinations, including measurements of biomarker levels indicating the magnitude of surgical stress (36-38), were used in our study. In ERAS group, the postoperative white blood cell count, percentage of neutrophil granulocytes (NEUT%), C-reactive protein (CRP), were significantly lower than those in the routine group, and the levels of albumin (ALB), prealbumin (PA) were significantly higher for patients in the ERAS group. Similar results were obtained in liver surgery (35). Procalcitonin (PCT) increases during severe generalized bacterial, parasitic, or fungal infections (39). Moreover, there was no significant difference in postoperative PCT between the two groups, perhaps due to the similar incidence rate of pneumonia (ERAS group: 5.6%, routine group: 8.8%, P=0.163).

In our study, we found lower incidences of PPCs in the ERAS group than in the control group, and the same results were observed

for atelectasis and air leakage (\geq 5 days). We suppose that early mobilization is crucial for reducing morbidity, promoting lung recruitment as soon as possible, promoting quick recovery of gastrointestinal function, and preventing deep venous thrombosis. Rogers LJ (19) also regarded early mobilization as the most important predictor. ERAS protocols tended to decrease the occurrence of pneumonia, although the difference was not significant. Urinary irritation was significantly lower in the ERAS group (6.2% vs. 25.5%, P<0.001), and acute urinary retention rarely occurred in the ERAS group, even for patients without perioperative transurethral catheters. Of the two patients with acute urinary retention, one man had urinary retention due to prostatitis, and the other patient, a woman, had urinary retention due to unknown reasons; she was cured after urinary catheterization.

We recommend that patients with fewer comorbidities, a smaller resection range, or less operation time be candidates for day surgery (from admission to discharge \leq 48 hours), although the management details still need exploration and optimization.

TABLE 6 Predictors of removal of the drainage the 1st day (without pneumonia) after surgery.

Predictor ^a	β value	Odds ratio (95% CI)	P value
Comorbidity			0.029
No comorbidity	Ref.	1	
One comorbidity	0.518	1.678 (0.905-3.112)	
two comorbidities	0.971	2.639 (0.551-12.641)	
≥3 comorbidities	1.204	3.333 (1.346- 8.254)	
Surgical procedures			0.001
Wedge resection	Ref.	1	
Segmentectomy	0.338	1.403 (0.629- 3.126)	
Lobectomy	1.182	3.261 (1.706- 6.232)	
Operation time	0.010	1.010 (1.000- 1.019)	0.039

^aMultivariate logistic regression analysis: gender (female: 0, male: 1), age (numerical variable), smoking status (never: 0, ever: 1), comorbidity (hypertension, diabetes mellitus, heart disease, brain vascular disease, COPD, no comorbidity: 0, one comorbidity: 1, two comorbidities: 2, ≥3 comorbidities: 3), surgical procedures (wedge resection: 0, segmentectomy: 1, lobectomy: 2), operation time (minutes, numerical variable), intraoperative blood loss (ml, numerical variable), removal of the drainage the 1st day (without pneumonia) (satisfied: 0, not satisfied: 1).

TABLE 7 Practice elements recommendations of multi- gradient individual ERAS (MGI- ERAS).

Items	Gradient 1	Gradient 2	Gradient 3
Preadmission information, education and counsellin	Simply completed during simple guidan c	ERAS group makes the simple guidan c	Specialized ERAS group makes systematic guidance on nutrition, smoking cessation, alcohol dependency management, and pulmonary prehabilitation
Airway management after admission	Climbing stairs and simple physical pulmonary training guided by surgeons or nurses	ERAS group guided the preoperative airway management	ERAS group including a specialized physiotherapist guided the preoperative airway management
Aspirin withdrawal or not (routinr minimally invasive surgery with low bleeding ris)	Aspirin withdrawal for at least one we	Aspirin withdrawal for 3-5 days then LMWH ^a bringing management	No aspirin withdrawal
Preoperative fasting and carbohtdrate treatment	Clear fluids be allowed up until 4 hours before the induction of anaesthesia and soilids until 8 hours before induction	Oral carbohydrate loading be allowed up until 2-4 hours before the induction of anaesthesia and solids until 8 hours before induction	Oral carbohtdrate loading be allowed up until 2 hoursv before the induction of anaesthesia and solids until 6 hours before induction
Preventing intraoperative Hypothermi	Temperature control of the operating room during surgery	Convective active warming devices used perioperatively	Continuous measurement of core temperature to guide the temperature control of the patients.
Urinary drainage (routine minimally invasive segmentectomy surgery without need for strict fluid management)	The transurethral catheter is moved immediately after the operation	Not routinely placed for patients undergo wedge resection	Not routinely placed for lobectomy, even for sleeve lobectomy or tracheal surgery with low bleeding ris
Anaesthetic protoco	A combination of regional and general anaesthetic techniques with lung protective strategies during one- lung ventilation	Completely tubeless protocol ^b for patients undergo wedge resection.	Completely tubeless protocol ^b for segmentectomy, lobectomy, even for sleeve lobectomy or tracheal surgery with low bleeding risk.
Surgical techniqu	Three- port minimally invasive surgery (including VATS and robotic surgery	Two- port minimally invasive surgery (including VATS and robotic surgery)	Uniport minimally invasive surgery (including VATS and robotic surgery)
Postoperative recovery Raising the head of bed (by ≥30°) Sit up straight 4- 6 hours Sit up straight 2 hours after returning to position and mobilization	Raising the head of bed (by ≥30°) immediately back to the general ward, patients should be mobilized within 24 hours of surgery	Sit up straight 4- 6 hours after returning to the general ward, try to leave the sickbed 6- 8 hours after returning to the general ward	Sit up straight 2 hours after returning tothe general ward, moderate ambulationis tried 4 hours after returning to the general ward
Postoperative water drinking and diet	Try water drinking 4- 6 hours after returning to the general ward if no PONV ^c occurs, semi- fluid diet is permitted	Try water drinking 2- 4 hours after returning to the general ward, if no PONV ^c occurs, semi- fluid diet is permitted. The nutrition procedures is better conducted by specialized nutritionists	Try water drinking ≤2 hours after returning to the general ward, if no PONV ^c occurs, semi- fluid diet is permitted. The nutrition procedure is better conducted by specialized nutritionists.
Removal of the chest Tubes	Thoracic closed drainage with negative pressure can be use for continuous air leak, chest tubes should be removed with the daily serous effusion without progressive bleeding or chylothorax)<200ml.	Thoracic closed drainage with negative pressure can be used for continuous air leak, chest tubes should be removed with the daily serous effusion (without progressive bleeding or chylothorax)≤300ml.	Thoracic closed drainage with negative pressure can be used for continuous air leak, chest tubes should be removed with the daily serous effusion (without progressive bleeding or chylothorax) ≤450ml.
ain relief regim	Multimodal analgesic regime is recommended	Multimodal analgesic regime with the minimized opioids education and pain management consultation is needed sometimes	Multimodal analgesic regime with the minimized opioids dosage, professional psychological counselling for anxious patients and additional techniques such as transcutaneous electrical nerve stimulation carried out by physiotherapist is used.

^aLMWH, low molecular weight heparin. ^bCompletely tubeless protocol: VATS surgery with both non-intubated intravenous anesthesia and no urinary catheterization protocol. ^cPONV, postoperative nausea and vomiting.

The results of this study were similar to some other studies (19, 28), and for postoperative hospital stay, PPCs like pneumonia and atelectasis, even better results were got in our study. The data couldn't be used to compare directly due to the difference of enrolled population and implementation details among these studies, but the positive effect of ERAS was confirmed. Furthermore, we propose the concept of multi-gradient individual ERAS (MGI-ERAS). This means that the ERAS protocol is comprehensively formulated and performed in a gradient manner according to the individual conditions of the institutions, anesthetists, surgeons, nurses and patients. This approach may be convenient for medical centers attempting to gradually implement the ERAS protocol. The suggested practice elements of the MGI-ERAS are shown in Table 7. The recommendations of Gradient 1 are relatively easier to follow, and the recommendations of Gradient 3 may be the ultimate ERAS practice at present.

There are several limitations that should not be ignored. First, this was a single-center study. Second, the patients were enrolled more than 2 years previously, and gains in ERAS experience are inevitable, which may have led to bias. Third, a blinded method could not be used in this study, and the timing of return to diet, mobilization, removal of the chest tube, and discharge from the hospital might have been biased or even affected by the patients or their relatives. Moreover, pain control, psychological variables, postoperative functional recovery efficacy and quality of life were not presented. Finally, the economic outcomes of the ERAS program were not explored in this study.

Conclusion

In conclusion, the implementation of the ERAS protocol led to earlier return to diet and mobilization, lower incidences of PPCs and urinary irritation without acute urinary retention, and shorter durations of drainage and postoperative hospital stay, thus providing better biological impacts for patients undergoing VATS lung resection. MGI-ERAS is recommended for the implementation of the ERAS protocol at different institutions with respect to the individual conditions of the patients.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by the Ethics Committee of the Second Hospital of Shandong University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

YD: Data curation, Formal Analysis, Writing – original draft, Writing – review & editing. LZ: Data curation, Formal Analysis, Writing – review & editing. LS: Data curation, Formal Analysis, Methodology, Supervision, Writing – review & editing. WZ: Data curation, Formal Analysis, Methodology, Writing – review & editing. PL: Data curation, Supervision, Writing – review & editing. BC: Data curation, Supervision, Writing – review & editing. BC: Data curation, Supervision, Writing – review & editing. ZT: Data curation, Formal Analysis, Writing – review & editing. YZ: Data curation, Formal Analysis, Funding acquisition, Methodology, Project administration, Software, Supervision, Writing – original draft, Writing – review & editing. XZ: Conceptualization, Formal Analysis, Funding acquisition, Investigation, Project administration, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study is funded by Taishan Scholar Project and Key Laboratory of Thoracic Cancer, Shandong University.

Acknowledgments

We thank doctor Ling Li from Cheeloo Hospital of Shandong University, Ning Li, He Zhang from The Second Hospital of Shandong University, for discussion, guidance or practice of anesthesia and the recovery after that.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. (1997) 78:606–17. doi: 10.1093/bja/78.5.606

2. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. *Ann Surg.* (2008) 248:189–98. doi: 10.1097/SLA.0b013e31817f2c1a

3. Roulin D, Donadini A, Gander S, Griesser A-C, Blanc C, Hübner M, et al. Costefectiveness of the implementation of an enhanced recovery protocol for colorectal surgery. *Br J Surg.* (2013) 100:1108–14. doi: 10.1002/bjs.9184

4. Joliat GR, Labgaa I, Petermann D, Hübner M, Griesser A-C, Demartines N, et al. Cost beneft analysis of an enhanced recovery protocol for pancreaticoduodenectomy. *Br J Surg.* (2015) 102:1676–83. doi: 10.1002/bjs.9957

5. Lee L, Mata J, Ghitulescu GA, Boutros M, Charlebois P, Stein B, et al. Costefectiveness of enhanced recovery versus conventional perioperative management for colorectal surgery. *Ann Surg.* (2015) 262:1026–33. doi: 10.1097/SLA. 000000000001019

6. Senturk JC, Kristo G, Gold J, Bleday R, Whang E. The development of enhanced recovery after surgery across surgical specialties. *J Laparoendosc Adv Surg Tech A*. (2017) 27:863–70. doi: 10.1089/lap.2017.0317

7. Ni X, Jia D, Chen Y, Wang L, Suo J. Is the enhanced recovery after surgery (ERAS) program effective and safe in laparoscopic colorectal cancer surgery? A meta-analysis of randomized controlled trials. *J Gastrointest Surg.* (2019) 23:1502–12. doi: 10.1007/s11605-019-04170-8

8. Keil DS, Schiff LD, Carey ET, Moulder JK, Goetzinger AM, Patidar SM, et al. Predictors of admission after the implementation of an enhanced recovery after surgery pathway for minimally invasive gynecologic surgery. *Anesth Analg.* (2019) 129:776–83. doi: 10.1213/ANE.00000000003339

9. Damania R, Cocieru A. Impact of enhanced recovery after surgery protocols on postoperative morbidity and mortality in patients undergoing routine hepatectomy: review of the current evidence. *Ann Transl Med.* (2017) 5:341. doi: 10.21037/atm.2017.07.04

10. Sharif-Askary B, Hompe E, Broadwater G, Anolik R, Hollenbeck ST. The effect of enhanced recovery after surgery pathway implementation on abdominal-based microvascular breast reconstruction. *J Surg Res.* (2019) 242:276–85. doi: 10.1016/j.jss.2019.04.062

11. Lin C, Wan F, Lu Y, Li G, Yu L, Wang M. Enhanced recovery after surgery protocol for prostate cancer patients undergoing laparoscopic radical prostatectomy. *J Int Med Res.* (2019) 47:114–21. doi: 10.1177/0300060518796758

12. Angus M, Jackson K, Smurthwaite G, Carrasco R, Mohammad S, Verma R, et al. The implementation of enhanced recovery after surgery (ERAS) in complex spinal surgery. *J Spine Surg.* (2019) 5:116–23. doi: 10.21037/jss.2019.01.07

13. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright. CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. *J Thorac Cardiovasc Surg.* (2008) 135:247–54. doi: 10.1016/j.jtcvs.2007.07.060

14. Boffa DJ, Kosinski AS, Furnary AP, Kim S, Onaitis MW, Tong BC, et al. Minimally invasive lung cancer surgery performed by thoracic surgeons as effective as thoracotomy. *J Clin Oncol.* (2018) 36:2378–85. doi: 10.1200/JCO.2018.77.8977

15. Caso R, Watson TJ, Khaitan PG, Marshall MB. Outcomes of minimally invasive sleeve resection. *J Thorac Dis.* (2018) 10:6653–9. doi: 10.21037/jtd.2018.10.97

16. Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS[®]) Society and the European Society of Thoracic Surgeons (ESTS). *Eur J Cardiothorac Surg.* (2019) 55:91– 115. doi: 10.1093/ejcts/ezy301

17. Gao S, Barello S, Chen L, Chen C, Che G, Cai K, et al. Clinical guidelines on perioperative management strategies for enhanced recovery after lung surgery. *Transl Lung Cancer Res.* (2019) 8:1174–87. doi: 10.21037/tlcr.2019.12.25

18. Brown JK, Singh K, Dumitru R, Chan E, Kim MP. The benefits of enhanced recovery after surgery programs and their application in cardiothoracic surgery. *Methodist Debakey. Cardiovasc J.* (2018) 14:77–88. doi: 10.14797/mdcj-14-2-77

19. Rogers LJ, Bleetman D, Messenger DE, Joshi NA, Wood L, Rasburn NJ, et al. The impact of enhanced recovery after surgery (ERAS) protocol compliance on morbidity from resection for primary lung cancer. *J Thorac Cardiovasc Surg.* (2018) 155:1843–52. doi: 10.1016/j.jtcvs.2017.10.151

20. Gonzalez M, Abdelnour-Berchtold E, Perentes JY, Doucet Valérie, Zellweger M, Marcucci C, et al. An enhanced recovery after surgery program for video- assisted thoracoscopic surgery anatomical lung resections is cost-effective. *J Thorac Dis.* (2018) 10:5879–88. doi: 10.21037/jtd.2018.09.100

21. Licker M, Karenovics W, Diaper J, Frésard I, Triponez Frédéric, Ellenberger C, et al. Short-term preoperative high-intensity interval training in patients awaiting lung

Cancer surgery: a randomized controlled trial. J Thorac Oncol. (2017) 12:323-33. doi: 10.1016/j.jtho.2016.09.125

22. Brocki BC, Andreasen JJ, Langer D, Souza DSR, Westerdahl E. Postoperative inspiratory muscle training in addition to breathing exercises and early mobilization improves oxygenation in high-risk patients after lung cancer surgery: a randomized controlled trial. *Eur J Cardio-thorac Surg.* (2016) 49:1483–91. doi: 10.1093/ejcts/ezv359

23. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Ann Intern Med.* (2010) 152(1):726–32. doi: 10.7326/0003-4819-152-11-201006010-00232

24. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. *Lancet (London England)*. (2002) 359:614–8. doi: 10.1016/S0140-6736(02)07750-4

25. Zheng Yu, Mao M, Ji M, Zheng Q, Liu L, Zhao Z, et al. Does a pulmonary rehabilitation based ERAS program (PREP) affect pulmonary complication incidence, pulmonary function and quality of life after lung cancer surgery? Study protocol for a multicenter randomized controlled trial. *BMC Pulm Med.* (2020) 20:44. doi: 10.1186/s12890-020-1073-6

26. Bailey KL, Merchant N, Seo Y-J, Elashoff D, Benharash P, Yanagawa J. Shortterm readmissions after open, thoracoscopic, and robotic lobectomy for lung Cancer based on the Nationwide readmissions database. *World J Surg.* (2019) 43:1377–84. doi: 10.1007/s00268-018-04900-0

27. Seder CW, Salati M, Kozower BD, Wright CD, Falcoz P-E, Brunelli A, et al. Variation in pulmonary resection practices between the society of thoracic surgeons and the European society of thoracic surgeons general thoracic surgery databases. *Ann Thorac Surg.* (2016) 101:2077–84. doi: 10.1016/j.athoracsur.2015.12.073

28. Wang C, Lai Y, Li P, Su J, Che G. Infuence of enhanced recovery after surgery (ERAS) on patients receiving lung resection: a retrospective study of 1749 cases. *BMC Surg.* (2021) 21:115. doi: 10.1186/s12893-020-00960-z

29. Lassen K, Coolsen MME, Slim K, Carli F, Aguilar-Nascimento JoséEde, Schäfer M, et al. Guidelines for perioperative care for pancreaticoduodenectomy: enhanced recovery after surgery (ERAS) Society recommendations. *Clin Nutr.* (2012) 31:817–30. doi: 10.1016/j.clnu.2012.08.011

30. Melloul E, Hübner M, Scott M, Snowden C, Prentis J, Dejong CHC, et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. *World J Surg.* (2016) 40:2425–40. doi: 10.1007/s00268-016-3700-1

31. Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERASVR) Society recommendations. *Br J Surg.* (2014) 101:1209–29. doi: 10.1002/bjs.9582

32. Nakada T, Shirai S, Oya Y, Takahashi Y, Sakakura N, Ohtsuka T, et al. Four hours postoperative mobilization is feasible after thoracoscopic anatomical pulmonary resection. *World J Surg.* (2021) 45:631–7. doi: 10.1007/s00268-020-05836-0

33. Ruiz-Tovar J, Muñoz JL, Gonzalez J, Garcia A, Ferrigni C, Jimenez M, et al. Creactive protein, fibrinogen, and procalcitonin levels as early markers of staple line leak after laparoscopic sleeve gastrectomy in morbidly obese patients within an Enhanced Recovery After Surgery (ERAS) program. *Surg Endoscopy.* (2017) 31:5283–5288. doi: 10.1007/s00464-017-5602-1

34. Liu X, Wang Y, Fu Z. Impact of enhanced recovery after surgery on postoperative neutrophil–lymphocyte ratio in patients with colorectal cancer. J Int Med Res. (2020) 48:30006052092594. doi: 10.1177/0300060520925941

35. Gonvers S, Jurt J, Joliat G-R, Halkic N, Melloul E, Hübner M, et al. Biological impact of an enhanced recovery after surgery programme in liver surgery. *BJS Open.* (2021) 5:zraa015. doi: 10.1093/bjsopen/zraa015

36. Nishiguchi K, Okuda J, Toyoda M, Tanaka K, Tanigawa N. Comparative evaluation of surgical stress of laparoscopic and open surgeries for colorectal carcinoma. *Dis Colon Rectum*. (2001) 44:223–30. doi: 10.1007/BF02234297

37. Warschkow R, Steffen T, Beutner U, Müller SA, Schmied BM, Tarantino I. Diagnostic accuracy of C-reactive protein and white blood cell counts in the early detection of inflammatory complications after open resection of colorectal cancer: a retrospective study of 1187 patients. *Int J Colorectal Dis.* (2011) 26:1405–13. doi: 10.1007/s00384-011-1262-0

38. Labgaa I, Joliat GR, Demartines N, Hubner M. Serum albumin is an early predictor of complications after liver surgery. *Dig Liver Dis.* (2016) 48:559–61. doi: 10.1016/j.dld.2016.01.004

39. Vijayan AL, Vanimaya, Ravindran S, Saikant R, Lakshmi S, Kartik R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *J Intensive Care.* (2017) 5:51. doi: 10.1186/s40560-017-0246-8